Place of Intrathecal CXCL-13 in the Diagnosis of Lyme Neuroborreliosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

141 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-13

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neuroborreliosis (NBL) is diagnosed in 10-15% of patients with Lyme borreliosis. In Europe in adults, the main clinical manifestation is called "Bannwarth syndrome". This includes painful meningoradiculitis, sometimes accompanied by cranial nerve neuritis. Current European guidelines issued by the European Federation of Neurological Societies (EFNS) recommend the following triad for the diagnosis of "definite NBL": (i) Neurological symptoms suggestive of NBL without any other obvious cause; (ii) CSF pleocytosis; (iii) Intrathecal production of specific anti-Borreliella antibodies. CXCL13, C-X-C chemokine motif ligand 13, is a chemokine implicated in B cell chemotaxis. Extensive literature exists on the analysis of CXCL13i as a diagnostic marker for acute NBL. A recent meta-analysis from 2018, published by Rupprecht et al finds an overall sensitivity and specificity of 89% and 96% respectively, indicating satisfactory diagnostic value. In this study, the investigators wish to assess the place of this new marker in the diagnosis of neuroborreliosis before proposing it as a test carried out by the Borrelia CNR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Manifestations and Long-Term Outcome in Early Lyme Neuroborreliosis

NCT04653558

Lyme Disease

COMPLETED

Study on Early Lyme Neuroborreliosis

NCT00910533

Nervous System Lyme Borreliosis

UNKNOWN NA

Erythema Migrans in Elderly

NCT03371563

Lyme Disease Erythema Migrans Elderly Infection

COMPLETED

Direct Diagnosis of Disseminated Lyme Borreliosis.

NCT04719962

Lyme Disease

UNKNOWN NA

Borrelia Species in Cutaneous Lyme Borreliosis

NCT00576082

Lyme Borreliosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lyme Borreliosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major subject (≥18 years old)
* Subject having consulted at the HUS between 01/01/2013 and 31/12/2018
* Subject not having, after being informed, expressed their opposition to the reuse of their data for the purposes of this research

Exclusion Criteria

* Subject who expressed their opposition to participating in the study
* Subject under guardianship or curatorship
* Subject under safeguard of justice

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No